Loading companies…
RI
RegCell, Inc.
United States · Biotech
RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | $44M | Playground Global — LeadAlumni Ventures — ParticipantFast Track Initiative — ParticipantGlobal Brain — ParticipantKyoto iCAP — ParticipantLG Technology Ventures — ParticipantMedical Incubator Japan — ParticipantMitsui Chemicals — ParticipantOsaka University Venture Capital — ParticipantThe University of Tokyo Edge Capital Partners (UTEC) — Participant |
Investors
Playground GlobalLed Series AAlumni VenturesJoined Series AFast Track InitiativeJoined Series AGlobal BrainJoined Series AKyoto iCAPJoined Series ALG Technology VenturesJoined Series AMedical Incubator JapanJoined Series AMitsui ChemicalsJoined Series AOsaka University Venture CapitalJoined Series AThe University of Tokyo Edge Capital Partners (UTEC)Joined Series ACoverage
Sep 15, 2026RegCell, Inc. · Series ASimilar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
AT